Among other findings, the use of the XVIVO device was associated with a numerically lower risk for the composite endpoint comprising cardiac-related mortality, cellular rejection, and graft dysfunction, corresponding to a relative risk reduction of 44%; however, this difference did not reach statistical significance and should therefore be interpreted as clinically meaningful rather than conclusive [ 29 ].
1
—
—